MedTrace Logo

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

NCT02032784 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-07-16

No results posted yet for this study

Summary

Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.

Conditions

  • Adenoma

Interventions

DRUG

octreotide

Octreotide 100mg subcutaneous every 8 hours for 5 days

OTHER

No Octreotide

No drug

Sponsors & Collaborators

  • AdventHealth

    lead OTHER

Principal Investigators

  • Robert Hawes, MD · AdventHealth

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2018-06-28
Completion
2020-07-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02032784 on ClinicalTrials.gov